Laurence Duvillard , Jean-Paul Pais de Barros , Alexia Rouland , Isabelle Simoneau , Damien Denimal , Benjamin Bouillet , Jean-Michel Petit , Bruno Vergès
{"title":"利拉鲁肽对 2 型糖尿病患者的高密度脂蛋白载脂蛋白 AI 动力学无影响","authors":"Laurence Duvillard , Jean-Paul Pais de Barros , Alexia Rouland , Isabelle Simoneau , Damien Denimal , Benjamin Bouillet , Jean-Michel Petit , Bruno Vergès","doi":"10.1016/j.diabet.2024.101535","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim</h3><p>The catabolism of high density lipoprotein (HDL) apolipoprotein AI (apoAI) is accelerated in patients with type 2 diabetes (T2D), related to hypertriglyceridemia, insulin resistance and low plasma adiponectin levels. Since liraglutide is likely to partly correct these abnormalities, we hypothesized that it might have a beneficial effect on HDL apoAI kinetics in patients with T2D.</p></div><div><h3>Methods</h3><p>An <em>in vivo</em> kinetic study of HDL apoAI was performed in 10 patients with T2D before and after 6 months of treatment with 1.2 mg/day of liraglutide, using a bolus of l-[1–<sup>13</sup>C]leucine followed by a 16-hour constant infusion.</p></div><div><h3>Results</h3><p>Liraglutide reduced BMI (34.9 ± 4.7 <em>vs</em> 36.6 ± 4.9 kg/m<sup>2</sup>, <em>P</em> = 0.012), HbA1c (7.1 ± 1.1 <em>vs</em> 9.6 ± 2.6%, <em>P</em> = 0.003), HOMA-IR (5.5 ± 1.9 <em>vs</em> 11.6 ± 11.2, <em>P</em> = 0.003), fasting triglycerides (1.76 ± 0.37 <em>vs</em> 2.48 ± 0.69 mmol/l, <em>P</em> < 0.001) and triglycerides during kinetics (2.34 ± 0.81 <em>vs</em> 2.66 ± 0.65 mmol/l, <em>P</em> = 0.053). Plasma HDL cholesterol and adiponectin concentrations were unchanged (respectively 0.97 ± 0.26 <em>vs</em> 0.97 ± 0.19 mmol/l, <em>P</em> = 1; 3169 ± 1561 <em>vs</em> 2618 ± 1651 µg/l, <em>P</em> = 0.160), similar to triglyceride content in HDL (5.13 ± 1.73 vs 5.39 ± 1.07%, <em>P</em> = 0.386). Liraglutide modified neither HDL apoAI fractional catabolic rate (0.35 ± 0.11 vs 0.38 ± 0.11 pool/day, <em>P</em> = 0.375), nor its production rate (0.44 ± 0.13 vs 0.49 ± 0.15 g/l/day, <em>P</em> = 0.375), nor its plasma concentration (1.26 ± 0.19 vs 1.29 ± 0.14 g/l, <em>P</em> = 0.386).</p></div><div><h3>Conclusion</h3><p>Six months of treatment with 1.2 mg/day of liraglutide had no effect on the kinetics of HDL apoAI in patients with T2D. The lack of decrease in triglyceride content in HDL related to an only moderate decrease in triglyceridemia, probably greatly explains these results. Insufficient improvement of insulin sensitivity and adiponectinemia may also be implied.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1262363624000272/pdfft?md5=919dc39fbfcf1c9138f9637d0e35003d&pid=1-s2.0-S1262363624000272-main.pdf","citationCount":"0","resultStr":"{\"title\":\"No effect of liraglutide on high density lipoprotein apolipoprotein AI kinetics in patients with type 2 diabetes\",\"authors\":\"Laurence Duvillard , Jean-Paul Pais de Barros , Alexia Rouland , Isabelle Simoneau , Damien Denimal , Benjamin Bouillet , Jean-Michel Petit , Bruno Vergès\",\"doi\":\"10.1016/j.diabet.2024.101535\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Aim</h3><p>The catabolism of high density lipoprotein (HDL) apolipoprotein AI (apoAI) is accelerated in patients with type 2 diabetes (T2D), related to hypertriglyceridemia, insulin resistance and low plasma adiponectin levels. Since liraglutide is likely to partly correct these abnormalities, we hypothesized that it might have a beneficial effect on HDL apoAI kinetics in patients with T2D.</p></div><div><h3>Methods</h3><p>An <em>in vivo</em> kinetic study of HDL apoAI was performed in 10 patients with T2D before and after 6 months of treatment with 1.2 mg/day of liraglutide, using a bolus of l-[1–<sup>13</sup>C]leucine followed by a 16-hour constant infusion.</p></div><div><h3>Results</h3><p>Liraglutide reduced BMI (34.9 ± 4.7 <em>vs</em> 36.6 ± 4.9 kg/m<sup>2</sup>, <em>P</em> = 0.012), HbA1c (7.1 ± 1.1 <em>vs</em> 9.6 ± 2.6%, <em>P</em> = 0.003), HOMA-IR (5.5 ± 1.9 <em>vs</em> 11.6 ± 11.2, <em>P</em> = 0.003), fasting triglycerides (1.76 ± 0.37 <em>vs</em> 2.48 ± 0.69 mmol/l, <em>P</em> < 0.001) and triglycerides during kinetics (2.34 ± 0.81 <em>vs</em> 2.66 ± 0.65 mmol/l, <em>P</em> = 0.053). Plasma HDL cholesterol and adiponectin concentrations were unchanged (respectively 0.97 ± 0.26 <em>vs</em> 0.97 ± 0.19 mmol/l, <em>P</em> = 1; 3169 ± 1561 <em>vs</em> 2618 ± 1651 µg/l, <em>P</em> = 0.160), similar to triglyceride content in HDL (5.13 ± 1.73 vs 5.39 ± 1.07%, <em>P</em> = 0.386). Liraglutide modified neither HDL apoAI fractional catabolic rate (0.35 ± 0.11 vs 0.38 ± 0.11 pool/day, <em>P</em> = 0.375), nor its production rate (0.44 ± 0.13 vs 0.49 ± 0.15 g/l/day, <em>P</em> = 0.375), nor its plasma concentration (1.26 ± 0.19 vs 1.29 ± 0.14 g/l, <em>P</em> = 0.386).</p></div><div><h3>Conclusion</h3><p>Six months of treatment with 1.2 mg/day of liraglutide had no effect on the kinetics of HDL apoAI in patients with T2D. The lack of decrease in triglyceride content in HDL related to an only moderate decrease in triglyceridemia, probably greatly explains these results. Insufficient improvement of insulin sensitivity and adiponectinemia may also be implied.</p></div>\",\"PeriodicalId\":11334,\"journal\":{\"name\":\"Diabetes & metabolism\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-04-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1262363624000272/pdfft?md5=919dc39fbfcf1c9138f9637d0e35003d&pid=1-s2.0-S1262363624000272-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes & metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1262363624000272\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & metabolism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1262363624000272","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
No effect of liraglutide on high density lipoprotein apolipoprotein AI kinetics in patients with type 2 diabetes
Aim
The catabolism of high density lipoprotein (HDL) apolipoprotein AI (apoAI) is accelerated in patients with type 2 diabetes (T2D), related to hypertriglyceridemia, insulin resistance and low plasma adiponectin levels. Since liraglutide is likely to partly correct these abnormalities, we hypothesized that it might have a beneficial effect on HDL apoAI kinetics in patients with T2D.
Methods
An in vivo kinetic study of HDL apoAI was performed in 10 patients with T2D before and after 6 months of treatment with 1.2 mg/day of liraglutide, using a bolus of l-[1–13C]leucine followed by a 16-hour constant infusion.
Results
Liraglutide reduced BMI (34.9 ± 4.7 vs 36.6 ± 4.9 kg/m2, P = 0.012), HbA1c (7.1 ± 1.1 vs 9.6 ± 2.6%, P = 0.003), HOMA-IR (5.5 ± 1.9 vs 11.6 ± 11.2, P = 0.003), fasting triglycerides (1.76 ± 0.37 vs 2.48 ± 0.69 mmol/l, P < 0.001) and triglycerides during kinetics (2.34 ± 0.81 vs 2.66 ± 0.65 mmol/l, P = 0.053). Plasma HDL cholesterol and adiponectin concentrations were unchanged (respectively 0.97 ± 0.26 vs 0.97 ± 0.19 mmol/l, P = 1; 3169 ± 1561 vs 2618 ± 1651 µg/l, P = 0.160), similar to triglyceride content in HDL (5.13 ± 1.73 vs 5.39 ± 1.07%, P = 0.386). Liraglutide modified neither HDL apoAI fractional catabolic rate (0.35 ± 0.11 vs 0.38 ± 0.11 pool/day, P = 0.375), nor its production rate (0.44 ± 0.13 vs 0.49 ± 0.15 g/l/day, P = 0.375), nor its plasma concentration (1.26 ± 0.19 vs 1.29 ± 0.14 g/l, P = 0.386).
Conclusion
Six months of treatment with 1.2 mg/day of liraglutide had no effect on the kinetics of HDL apoAI in patients with T2D. The lack of decrease in triglyceride content in HDL related to an only moderate decrease in triglyceridemia, probably greatly explains these results. Insufficient improvement of insulin sensitivity and adiponectinemia may also be implied.
期刊介绍:
A high quality scientific journal with an international readership
Official publication of the SFD, Diabetes & Metabolism, publishes high-quality papers by leading teams, forming a close link between hospital and research units. Diabetes & Metabolism is published in English language and is indexed in all major databases with its impact factor constantly progressing.
Diabetes & Metabolism contains original articles, short reports and comprehensive reviews.